Breaking News
Get 50% Off 0
🤔 Tesla Q2 earnings report - is now the right time to buy?
Explore Tesla Data
Close

JCR Pharmaceuticals Co Ltd (4552)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
667.0 +2.0    +0.30%
- Closed. Currency in JPY
Type:  Equity
Market:  Japan
ISIN:  JP3701000006 
  • Volume: 1,412,100
  • Bid/Ask: 666.0 / 668.0
  • Day's Range: 655.0 - 682.0
JCR Pharmaceuticals 667.0 +2.0 +0.30%

JCR Pharmaceuticals Co Ltd Company Profile

 
Get an in-depth profile of JCR Pharmaceuticals Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

934

Equity Type

ORD

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was founded in 1975 and is based in Ashiya, Japan.

Contact Information

Address 3-19 Kasuga-cho
Ashiya, 659-0021
Japan
Phone 81 7 9732 8591
Fax -

Top Executives

Name Age Since Title
Philippe Fauchet 66 - Independent Outside Director
Marc Dunoyer 71 2023 Independent Outside Director
Toru Ashida 56 2015 Director, Senior Managing Executive Officer of Sales & Executive Director of Sales Division
Takashi Suetsuna 75 - Independent Outside Director
Toshihide Yoda 61 - Independent Outside Director
Yutaka Atomi 80 2022 Independent Outside Director
Yuko Hayashi 59 - Independent Outside Director
Shin Ashida 81 2005 Chairman, CEO, President & COO
Hiroyuki Sonoda 46 2018 Senior Managing Executive Officer of Research, Executive Director of Research Division and Director
Andrea Spezzi 59 2024 Director & Managing Executive Officer of Development Division
Yoshio Hiyama 64 2021 Director, Managing Exec. Officer of Quality Assurance & Exec. Dir. of Quality Assurance Div.
Kazumasa Oizumi 78 2013 Outside Audit & Supervisory Board Member
Miya Miyama - 2025 Audit & Supervisory Board Member
Masayuki Mitsuka - 2025 Audit & Supervisory Board Member
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4552 Comments

Write your thoughts about JCR Pharmaceuticals Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email